Tursz T, Hors J, Lipinski M, Amiel J L
C R Acad Hebd Seances Acad Sci D. 1977 Dec 19;285(16):1585-7.
HLA phenotypes of 13 patients surviving in lasting first remission over 6 years after BCG immunotherapy for acute childhood lymphoblastic leukaemia (ALL) were compared to phenotypes of normal subjects and of surviving ALL patients treated exclusively with chemotherapy. Among the BCG-treated patients, the frequency of the antigen HLA-BW 17 was 46.1% vs 7.3% in healthy controls (p less than 0.001) and the frequency of the antigen HLA-AW 33 was 30.8% vs 1.2% (p less than 0.001). 9 patients possessed at least one of these two antigens (69.2% vs 8% in controls p less than 0.001). Phenotypes of the chemotherapy-treated patients did not differ significantly from controls. These results suggest the existence in humans of HLA-linked genes which are involved in the response to BCG immunotherapy in ALL.
对13例急性儿童淋巴细胞白血病（ALL）患者在卡介苗免疫治疗后持续首次缓解6年以上的HLA表型，与正常受试者以及仅接受化疗的存活ALL患者的表型进行了比较。在接受卡介苗治疗的患者中，抗原HLA - BW 17的频率为46.1%，而健康对照中为7.3%（p小于0.001），抗原HLA - AW 33的频率为30.8%，而对照中为1.2%（p小于0.001）。9例患者拥有这两种抗原中的至少一种（69.2%，而对照中为8%，p小于0.001）。接受化疗患者的表型与对照无显著差异。这些结果表明人类中存在与HLA相关的基因，它们参与了ALL患者对卡介苗免疫治疗的反应。
